October 2, 2025
1 min read

Ansa snares $54.4M in series B financing to boost its DNA synthesis platform

Ansa Biotechnologies hauled in a total of $54.4 million in an oversubscribed series B financing round that will be used to expand the company’s DNA synthesis production capacity in the U.S.

Leave a Reply

Your email address will not be published.

Previous Story

The role of Fusobacterium colorectal cancer

Next Story

Vaxcyte strikes up to $1B deal for fill-finish space at Thermo Fisher’s N.C. production facility

Previous Story

The role of Fusobacterium colorectal cancer

Next Story

Vaxcyte strikes up to $1B deal for fill-finish space at Thermo Fisher’s N.C. production facility

Latest from Blog

FDA finally analyzed its own youth tobacco data

Get your daily dose of health and medicine every weekday with STAT’s free newsletter Morning Rounds. Sign up here. Good morning. A lot of people had reactions, comments, and theories regarding Lizzy’s story
Go toTop